Shares of Trinity Biotech plc (NASDAQ:TRIB) passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $1.91 and traded as high as $2.41. Trinity Biotech shares last traded at $2.25, with a volume of 4,198 shares.
The company has a debt-to-equity ratio of 1.86, a current ratio of 4.30 and a quick ratio of 2.74. The stock has a market cap of $53.13 million, a P/E ratio of 17.58 and a beta of 1.33. The stock has a fifty day moving average price of $1.92.
Trinity Biotech (NASDAQ:TRIB) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.06). Trinity Biotech had a positive return on equity of 3.20% and a negative net margin of 23.81%. The firm had revenue of $22.03 million during the quarter.
Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in Trinity Biotech in the 4th quarter worth about $141,000. Lapides Asset Management LLC lifted its stake in Trinity Biotech by 2.1% in the 1st quarter. Lapides Asset Management LLC now owns 655,600 shares of the company’s stock worth $1,868,000 after purchasing an additional 13,700 shares in the last quarter. Finally, Hunter Associates Investment Management LLC lifted its stake in Trinity Biotech by 10.8% in the 1st quarter. Hunter Associates Investment Management LLC now owns 1,078,610 shares of the company’s stock worth $3,074,000 after purchasing an additional 104,928 shares in the last quarter. Institutional investors own 54.44% of the company’s stock.
About Trinity Biotech (NASDAQ:TRIB)
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes.
Recommended Story: What is Depreciation?
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.